French Observatory of ElectroConvulsive Therapy (ECT)
Observatoire National d'ElectroConvulsivoThérapie (ECT)
1 other identifier
observational
2,000
1 country
30
Brief Summary
Since the 30s, ECT has been a psychiatric treatment mainly used for drug-resistant depressive illnesses. Clinical studies have shown its therapeutic efficiency compared to standard treatments also in other psychiatric illnesses. Although efficient, ECTs also induce side effects. In France, there is currently no consensus on providing the suitest medical care. It is therefore important to review our nowadays health care models in order to maintain and improve the recommendations of the French National Agency for Accreditation and Evaluation in Health, the last of which date from 1997! Within this context, this project has the dual objective of (1) identifying ECT medical procedure in France and (2) developing research to evaluate and to improve the effectiveness of this treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2018
Longer than P75 for all trials
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 24, 2018
CompletedFirst Submitted
Initial submission to the registry
July 15, 2020
CompletedFirst Posted
Study publicly available on registry
July 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
August 20, 2024
August 1, 2024
9.6 years
July 15, 2020
August 19, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
ECT efficiency on patients
2018-2022
Eligibility Criteria
All patients receiving ECT as part of their medical treatment
You may qualify if:
- Patients consecutively referred for ECT.
You may not qualify if:
- Not specified
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (30)
CHU d'Angers : Site Larrey
Angers, France
Clinique Mirambeau
Anglet, France
CHS de Montfavet
Avignon, France
CH Cote Basque
Bayonne, France
Fondation bon sauveur
Bégard, France
Centre de crise Esquirol
Caen, France
CHU Gabriel Montpied
Clermont-Ferrand, France
CH La Chartreuse
Dijon, France
Clinique du domaine de Vontes
Esvres-sur-Indre, France
Clinique de Pen-An-Dalar
Guipavas, France
CUMP Océan Indien
La Réunion, France
CH Marius Lacroix
La Rochelle, France
Césame
Les Ponts-de-Cé, France
CH de Mayenne
Mayenne, France
CHR Metz-Thionville
Metz, France
CH psy de la drôme Vivarais
Monteléger, France
CHS la Colombiere
Montpellier, France
CH Saint Roch
Nice, France
CH Sainte Anne
Paris, France
CH Henri Laborit
Poitiers, 86000, France
CHI Redon-Carentoir
Redon, France
CH Guillaume Regnier
Rennes, France
CH du Rouvray
Rouen, France
Epsm du Morbihan
Saint-Avé, France
Clinique Villa du Parc
Saujon, France
CH Civil 1
Strasbourg, France
CH Nord Deux Sèvres
Thouars, France
CHITS CH Sainte Musse
Toulon, France
CH Purpan
Toulouse, France
CPU de Tours
Tours, France
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 15, 2020
First Posted
July 20, 2020
Study Start
April 24, 2018
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
August 20, 2024
Record last verified: 2024-08